- 积分
- 918
- 威望
- 918
- 包包
- 2980
|
Very interesting: Why there are TP53 mutation in non-cancer samples? Really feel surprising??5 m: P& n/ O4 S
; J+ O7 O" k4 O" |" X6 _
http://www.ncbi.nlm.nih.gov/pubmed/27377626
. I3 K2 q( T; p% U- ^7 F7 t5 k: t& e+ b9 ?; c7 Y
Identification of Circulating Tumor DNA for the Early Detection of Small-cell Lung Cancer.
/ T% U- u. `% F; R, |/ o! h* M, a2 J6 h' Z
Circulating tumor DNA (ctDNA) is emerging as a key potential biomarker for post-diagnosis surveillance but it may also play a crucial role in the detection of pre-clinical cancer. Small-cell lung cancer (SCLC) is an excellent candidate for early detection given there are no successful therapeutic options for late-stage disease, and it displays almost universal inactivation of TP53. We assessed the presence of TP53 mutations in the cell-free DNA (cfDNA) extracted from the plasma of 51 SCLC cases and 123 non-cancer controls. We identified mutations using a pipeline specifically designed to accurately detect variants at very low fractions. We detected TP53 mutations in the cfDNA of 49% SCLC patients and 11.4% of non-cancer controls. When stratifying the 51 initial SCLC cases by stage, TP53 mutations were detected in the cfDNA of 35.7% early-stage and 54.1% late-stage SCLC patients. The results in the controls were further replicated in 10.8% of an independent series of 102 non-cancer controls. The detection of TP53 mutations in 11% of the 225 non-cancer controls suggests that somatic mutations in cfDNA among individuals without any cancer diagnosis is a common occurrence, and poses serious challenges for the development of ctDNA screening tests. |
-
总评分: 威望 + 2
包包 + 10
查看全部评分
|